Psychiatric Journals
Psychiatry
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?


Article ID

Home
General Psychiatry
Messages
Conferences
Jobs
Newsletters
My Library
Topics in
Psychiatry
        Anxiety
        Child/Adolescent Psych
        Eating Disorders
        Economics of Medicine
        Geriatric Psych
        Mood Disorders
        Neuro/Psych Pharmacol
        Neuropsych Sciences
        Other Psychiatry
        Pain Management
        Personality Disorders
        Popular Press
        Psychotherapy/analysis
        Schizophrenia/Psychosis
        Substance Abuse
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
Top Ten Searches
post partum depression  post partum depression
ssri  ssri
pervasive developmental  pervasive developmental
adhd  adhd
alzheimer's  alzheimer's
nervosa  nervosa
ptsd  ptsd
bipolar  bipolar
personality  personality
methamphetamine  methamphetamine
 
Sponsor
MDLinx Email Article

To email this article, enter your own "From Email" address,
the recipient's "To Email" address, and click the "Send Email" button.
You may send to up to 5 email addresses.
*From Email:  
*To Email:  
To Email:  
To Email:  
To Email:  
To Email:  
Treatment of fibromyalgia syndrome with gabapentin and pregabalin – A meta-analysis of randomized controlled trials
Häuser W et al. - Study concludes that the usage of gabapentin (GPT) and pregabalin (PGB) can be considered for the treatment of pain and sleep disturbances in FMS patients. Because of some dose-dependent relevant side effects of both drugs the treatment should start with low dosage and then increased slowly with small dosages.

Methods
  • Aim of this systematic review and meta-analysis was to determine the clinical relevance of GPT/PGB for the treatment of FMS
  • MEDLINE, PsycINFO, SCOPUS, www.clinicaltrials.org, the Cochrane Library (through October 2008), and the reference sections of original studies on GPT/PGB in FMS were searched
  • Randomized controlled trials (RCTs) on the treatment of FMS with GPT and PGB were analyzed
  • 6/127 RCTs studying 2422 subjects on treatment with GPT (1 study) or PGB (5 studies) and 1056 subjects on placebo with a median treatment duration of 11wks were included

Results
  • Strong evidence for a reduction of pain, improved sleep and improved health-related quality of life (HRQOL) but not for depressed mood
  • There was strong evidence for a non-substantial reduction of fatigue and of anxiety
  • The external validity of the studies was limited because pts with severe somatic and mental disorders were excluded
[more...]
Sponsor

Read a Different Specialty

Psychiatric News
Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics
Pain
Pediatrics
Practice Management
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology

Psychiatric News Profession Index

Psychiatric News
Dentist
Hospital Administrator
Nurse
    Medical Students
Nurse Practitioner
Pharma/Drug Marketer
    Pharmacist
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
Sponsor
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2009 MDLinx, Inc.